CervoMed to Showcase Neflamapimod Progress at Canaccord Growth Conference
Event summary
- CervoMed to present at Canaccord Genuity Growth Conference on August 11, 2026.
- Fireside chat will highlight recent progress in neflamapimod's clinical development program.
- Phase 3 trial initiation for DLB depends on securing partnership/financing.
- Interim biomarker data from nfvPPA trial expected in Q4 2026.
- EXPERTS-ALS Phase 2a trial dosing to begin in Q4 2026.
The big picture
CervoMed's participation in the Canaccord conference comes as biotech investors increasingly focus on neurodegenerative disease treatments with clear regulatory pathways. The company's progress with neflamapimod positions it within a competitive landscape of small-molecule therapies targeting neuroinflammation, though its ability to secure financing will determine the speed of clinical advancement.
What we're watching
- Financing Requirements
- Whether CervoMed can secure necessary partnership/financing to initiate Phase 3 DLB trial.
- Clinical Data
- The pace at which interim biomarker data from nfvPPA trial could influence investor sentiment.
- Regulatory Pathway
- How FDA alignment on registration path for neflamapimod in DLB will impact development strategy.
Related topics